Background: To investigate mechanisms underlying our previous observation of a
| INTRODUCTION
Sexually transmitted infections (STIs) have long been hypothesized to contribute to prostate carcinogenesis. Early proposed mechanisms focused around prostate epithelial cell transformation and induction of intraprostatic inflammation and prostate cell damage, 1,2 as a large proportion of STIs resulted in acute or chronic clinical prostatitis in the pre-antibiotic era. [3] [4] [5] However, now that most STIs can be readily diagnosed and treated, and STI-associated clinical prostatitis is rare, the relevance of STIs for prostate cancer (PCa) risk warrants confirmation.
We previously investigated this question by using serum prostatespecific antigen (PSA) as a marker of prostate involvement during infection (ie, prostate infection, inflammation, and/or cell damage) in two studies of young men. 6, 7 Both of these studies observed that men with exudative STIs (chlamydia, gonorrhea, Trichomonas vaginalis infection, and non-gonococcal urethritis) were more likely to have a large PSA rise at the time of their infection than non-infected controls.
We interpreted these findings to mean that some STIs had ascended to the prostate and contributed to a local inflammatory immune response and tissue injury, with subsequent release of PSA into the interstitial space and vasculature-that is, a "direct" prostate-specific mechanism.
However, as PSA also rose during infectious mononucleosis (IM) and other systemic or localized, non-genitourinary infections, 8 the possibility of "indirect" mechanisms for PSA elevation (eg, inflammation-mediated or pre-existing prostate damage together with increased vascular permeability) 8 was raised.
Therefore, to help disentangle the relative contributions of direct versus indirect mechanisms for PSA elevation, we measured serum high-sensitivity C-reactive protein (hsCRP), a non-specific marker of systemic inflammation derived from the liver, 9 in men from our previous study 7, 8 and compared our findings to those for PSA.
| MATERIALS AND METHODS

| Study population
We performed our study among US active-duty military members with stored sera in the Department of Defense Serum Repository (DoDSR).
This repository contains sera remaining from routine human immunodeficiency virus type 1 (HIV-1) testing of all active-duty military personnel since the early 1990s, as well as sera collected for indicated HIV-1 testing (eg, clinical work-up for STIs), pre-induction, major overseas deployments, and specialized physical examinations. These specimens are linked to information on demographics, service-related activity, and reportable (eg, chlamydia, gonorrhea, and NCNGU) and non-reportable medical diagnoses (eg, IM and other infectious diseases). [10] [11] [12] These diagnoses are recorded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. 10 Men eligible for our study were HIV-negative, <25 years of age as 
| Case definitions
Exudative STI cases were defined as men with a laboratory- 
| Specimen selection
We selected two serum specimens for each participant. For STI cases, we selected one specimen within 7 days of their case diagnosis ("index" specimen), and the first specimen collected before their index specimen ("pre-index" specimen, range: 9 days-4 years before diagnosis 
| hsCRP and PSA measurement
We measured serum hsCRP concentration using an automated latexenhanced immunoturbidometric assay (lower limit of detection = 0.03 mg/L) performed on a Behring BN II nephelometer (Dade Behring, Deerfield, IL). 13 Serum total PSA concentration was measured in the same specimens as part of our previous analysis using an Access
Hybritech assay (Beckman Coulter, Brea, CA). Specimens from the same participant were tested adjacent to one another in random within-and across-participant order, and laboratory members were blinded to the case-control status of all specimens. Assay reproducibility was assessed by including blinded, duplicate quality control pairs from the DoDSR in the testing sequence. The coefficient of variation was 3.5% for hsCRP (n = 23 pairs) and 12.4% for PSA (n = 25 pairs); it improved to 6.9% after excluding one largely discrepant pair.
| Statistical analysis
We initially explored the change in hsCRP during infection by | 1327 or after (controls) their index specimen; (2) participants with "clinically indicated" or "STI visit" reasons for blood draw for their pre-index (cases and controls) or index (controls only) specimens; (3) higher ranking officers who may have greater access to nonmilitary healthcare; and (4) men with active-duty breaks or deployment one year before their pre-index specimen through to 7 days after their index specimen. This last sensitivity analysis also excluded periods of time with potentially greater levels of acute stress, which have been hypothesized, but not found, to be associated with elevated hsCRP. [14] [15] [16] Similar results were observed in all sensitivity analyses as in the main analyses.
Finally, we examined the correlation between hsCRP and PSA in both pre-index and index specimens, and adjusted our original PSA findings for hsCRP. 3 At the time of blood draw of the index specimen. 4 Chlamydia, gonorrhea, NCNGU, and IM cases were frequency-matched as a group to controls by race/ethnicity. 5 Indicates blood drawn for routine and pre-and post-deployment HIV-1 tests, as well as HIV-1 tests performed as part of specialized physical examinations (eg, for flight school). 6 The mean time between pre-index and index specimens for the other infectious disease controls was 53.1 months. hsCRP, high-sensitivity C-reactive protein; NCNGU, non-chlamydial, non-gonococcal urethritis.
1 P values were calculated by linear regression with robust variance estimation for continuous variables, by linear regression for binary variables, and by logistic regression for categorical variables. All models were adjusted for race (African-American, non-African-American) to account for frequency-matching. 2 Values were calculated by linear regression with robust variance estimation for continuous variables, and by linear regression for binary and categorical variables. All models were adjusted for race to account for frequency-matching.
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and gonorrhea were less likely to be married, STI cases were more likely to be enlisted, and all cases, except IM, were less likely to have had their index specimen drawn for routine purposes, and more likely to have a greater number of blood draws for HIV-1 testing than controls. STI cases also had a shorter mean time between specimens than controls, whereas IM cases had a greater mean time (Table 1) .
| Exudative STIs
Gonorrhea cases had a significantly greater increase in geometric mean hsCRP and a borderline significant increase in mean hsCRP between their pre-index and index specimens than controls. They were also significantly more likely to have large absolute and relative rises in hsCRP, high-sensitivity C-reactive protein; IM, infectious mononucleosis. 1 P values were calculated by linear regression with robust variance estimation for continuous variables, by linear regression for binary variables, and by logistic regression for categorical variables. All models were adjusted for race (African-American, non-African-American) and window of specimen collection to account for frequency-matching. 2 Includes men with the following diagnoses: streptococcal sore throat (ICD-9-CM code = 034.0), influenza (codes = 487.1, 487.8), Haemophilus influenzae infection (code = 041.5), intestinal infection due to specified or unspecified organisms (codes = 008.43, 008.69, 008.8, 009.0), unspecified viral infection (code = 079.99), other specified viral infection (code = 079.89), unspecified infectious and parasitic diseases (code = 136.9), fever not accompanied by another diagnosis (code = 780.6), chicken pox and shingles (codes = 052.9, 053.0), and leptospirosis icterohemorrhagica (code = 100.0). 3 Values were calculated by linear regression with robust variance estimation for continuous variables, and by linear regression for binary and categorical variables. All models were adjusted for race and window of specimen collection to account for frequency-matching. 4 Additionally adjusted for age and time between pre-and index specimens.
hsCRP, and non-significantly more likely to have rises of any magnitude than controls, whereas no differences were observed for chlamydia or NCNGU (Table 2) .
| Infectious mononucleosis
No differences were observed in the average or full distribution of hsCRP change between IM cases and controls (Table 3 ). In analyses stratified by time between diagnosis and index specimen collection, cases whose index specimen was collected <4 or 4-12 months after diagnosis were non-significantly more likely to have a rise of any magnitude than controls, whereas those whose index specimen was collected >1 year after diagnosis were significantly less likely to have a large hsCRP rise. Combining our findings for index specimens collected within the first year of diagnosis resulted in a marginally significant association between IM and any rise in hsCRP, indicating that our overall findings were attenuated by inclusion of cases whose index specimen was collected >1 year after diagnosis (Table 4 ).
| Other systemic or localized, non-genitourinary infections
Infectious disease cases had a non-significantly greater change in geometric, but not arithmetic, mean hsCRP between their preindex and index specimens than controls. Cases were also nonsignificantly more likely to have a large relative rise and significantly more likely to have a rise of any magnitude than controls (Table 3) . In stratified analyses, cases whose index specimen was collected 4-12 months after diagnosis were nonsignificantly more likely to have a large relative rise and a rise of any magnitude than controls, as were cases with unspecified viral infections ( Table 4 ).
| hsCRP and PSA
Irrespective of infection type, the correlation between hsCRP and PSA was low when measured in the same specimen (pre-index specimens:
Spearman r = −0.0058; index specimens: r = 0.031). In addition, hsCRP, high-sensitivity C-reactive protein 1 All values were calculated by linear regression adjusting for race, window of specimen collection, age, and time between pre-and index specimens.
2 P values were calculated by linear regression adjusting for race, window of specimen collection, age, and time between pre-and index specimens for the infectious mononucleosis analysis; and by conditional logistic regression for the other infectious disease analysis. 3 P-value for comparison between cases and controls. 4 Combining results for <4 months and 4-12 months, the percentages were 72.0% for cases and 54.0% for controls, P = 0.056. 5 P-interaction. 6 Includes men with the following diagnoses: streptococcal sore throat (ICD-9-CM code = 034.0), influenza (codes = 487.1, 487.8), Haemophilus influenzae infection (code = 041.5), intestinal infection due to specified or unspecified organisms (codes = 008.43, 008.69, 008.8, 009.0), unspecified viral infection (code = 079.99), other specified viral infection (code = 079.89), unspecified infectious and parasitic diseases (code = 136.9), fever not accompanied by another diagnosis (code = 780.6), chicken pox and shingles (codes = 052.9, 053.0), and leptospirosis icterohemorrhagica (code = 100.0). IM, infectious mononucleosis; NCNGU, non-chlamydial, non-gonococcal urethritis; PSA, prostate-specific antigen. 1 Further details and complete results for these infectious diseases are presented in references. Calculated by linear regression adjusting for race for chlamydia, gonorrhea, and NCNGU; and for race, window of specimen collection, age, and time between pre-and index specimens for IM and other infectious diseases. 4 Calculated by Poisson regression with robust variance estimation adjusting for race for chlamydia, gonorrhea, and NCNGU; and adjusting for race, window of specimen collection, age, and time between pre-and index specimens for IM and other infectious diseases.
adjustment for hsCRP did not change our previous PSA results (Table 5 ).
| DISCUSSION
In this large, longitudinal study of infections and hsCRP, we found that only gonorrhea cases were significantly more likely to have a large hsCRP rise during infection than controls. However, gonorrhea, IM, and other systemic or localized, non-genitourinary cases were more likely to have a rise of any magnitude up to 1 year post-diagnosis than controls, possibly suggesting unresolved systemic inflammation in some infected men. Finally, compared to our findings for PSA (ie, large rises for chlamydia, gonorrhea, IM, and other infectious diseases), our findings for hsCRP were generally distinct and adjustment for hsCRP did not alter our previous PSA results. These contrasting patterns of findings support both direct and indirect mechanisms for PSA elevation.
To our knowledge, only two studies have examined the influence of STIs on hsCRP or CRP. 17, 18 The first of these studies observed higher levels of CRP in pregnant women with Trichomonas vaginalis infection than in those without infection, 17 and the second observed higher levels in C trachomatis positive women with mucopurulent cervicitis (ie, symptomatic infection) or infertility than in asymptomatic, C trachomatis positive women. 18 While these findings are difficult to compare directly to our results because we do not have information on symptoms, we believe our results are consistent with these findings based on the typical presentation of chlamydia and gonorrhea in men.
For instance, gonorrhea tends to cause symptomatic urethritis in men, 19 which may explain its positive association with hsCRP, whereas chlamydia tends to be asymptomatic, 19 However, despite the strong likelihood that we missed infectionassociated hsCRP peaks, we did observe positive associations for rises of any magnitude, possibly suggesting unresolved systemic inflammation in some infected men.
In addition to understanding the influence of infections on hsCRP, a major objective of our study was to help interpret our previous findings for infections and PSA. In the case of gonococcal infections that resulted in a large hsCRP but not PSA rise, we suspect these reflected symptomatic urethral infections that contributed to both a systemic immune response and prompt antibiotic therapy, thereby preventing prostate infection. In contrast, for gonococcal and chlamydial infections that resulted in a large PSA but not hsCRP rise, we suspect these likely reflected asymptomatic urethral infections that were not treated promptly, thereby allowing establishment of a chronic, low-grade prostatic infection, or damage to the prostate epithelium from persistent local urethral inflammation. 8 Finally, in the case of systemic or localized non-genitourinary infections that resulted in large sustained rises in PSA but not hsCRP, we hypothesize these may be explained by at least two 
| CONCLUSIONS
In summary, we found that hsCRP rose during some gonococcal infections in young men, but not during chlamydia or NCNGU infections.
hsCRP was also only minimally elevated months after IM or other systemic or local non-genitourinary infections, implying at least partial resolution of systemic inflammation by the time of blood draw. These results stand in contrast to previous findings for PSA, 7, 8 suggesting distinct infection-mediated mechanisms for PSA and hsCRP elevation, and supporting both direct and indirect mechanisms for our previous PSA findings. Future studies should explore these findings further for their relevance to both PSA-based PCa screening and risk. 
